Anatara Lifesciences Ltd
Research Anatara Lifesciences Ltd (ANR) on Bullrun: market cap AUD 2.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANR
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 2.84M
- Financial periodFY2025
- RevenueAUD 970.00K
- Revenue growth51.6%
- Net income-AUD 1.95M
- Free cash flow-AUD 2.27M
- Gross margin-64.9%
Valuation Snapshot
latest market cap is AUD 2.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 970.00K | -AUD 1.95M | -AUD 2.27M | -64.9% | -0.01 | AUD 100.00K | AUD 410.00K | AUD 540.00K |
| FY2024 | AUD 640.00K | -AUD 1.45M | -AUD 1.25M | -15.6% | -0.01 | AUD 1.03M | n/a | AUD 1.36M |
| FY2023 | n/a | -AUD 2.02M | -AUD 2.26M | n/a | -0.02 | AUD 351.18K | n/a | AUD 924.54K |
| FY2022 | n/a | -AUD 2.53M | -AUD 2.24M | n/a | -0.03 | AUD 1.12M | AUD 65.80K | AUD 1.36M |
| FY2021 | n/a | -AUD 2.00M | -AUD 2.10M | n/a | -0.03 | AUD 3.43M | AUD 79.92K | AUD 3.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | AUD 2.84M | n/a | n/a | n/a |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anatara Lifesciences Ltd's market cap?
Anatara Lifesciences Ltd's market capitalization is AUD 2.84M.
What does Anatara Lifesciences Ltd do?
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control.